Pulmonx (LUNG) Competitors

Pulmonx (NASDAQ:LUNG) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, community ranking, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Does the media prefer LUNG or MDXG?

In the previous week, MiMedx Group had 7 more articles in the media than Pulmonx. MarketBeat recorded 12 mentions for MiMedx Group and 5 mentions for Pulmonx. MiMedx Group's average media sentiment score of 1.42 beat Pulmonx's score of 1.24 indicating that MiMedx Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulmonx	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiMedx Group	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate LUNG or MDXG?

Pulmonx currently has a consensus price target of $12.75, suggesting a potential upside of 159.15%. MiMedx Group has a consensus price target of $12.00, suggesting a potential upside of 76.47%. Given Pulmonx's higher probable upside, equities research analysts clearly believe Pulmonx is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
MiMedx Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community favor LUNG or MDXG?

MiMedx Group received 11 more outperform votes than Pulmonx when rated by MarketBeat users. Likewise, 82.46% of users gave MiMedx Group an outperform vote while only 45.57% of users gave Pulmonx an outperform vote.

Company	Underperform	Outperform
Pulmonx	Outperform Votes 36 45.57%	Underperform Votes 43 54.43%
MiMedx Group	Outperform Votes 47 82.46%	Underperform Votes 10 17.54%

Which has better earnings and valuation, LUNG or MDXG?

MiMedx Group has higher revenue and earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$83.79M	2.36	-$60.84M	-$1.44	-3.42
MiMedx Group	$348.88M	2.87	$58.23M	$0.28	24.29

Which has more risk and volatility, LUNG or MDXG?

Pulmonx has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500.

Do insiders & institutionals have more ownership in LUNG or MDXG?

91.0% of Pulmonx shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 5.7% of Pulmonx shares are held by company insiders. Comparatively, 1.3% of MiMedx Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Is LUNG or MDXG more profitable?

MiMedx Group has a net margin of 23.86% compared to Pulmonx's net margin of -67.31%. MiMedx Group's return on equity of 26.21% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-67.31%	-55.36%	-33.53%
MiMedx Group	23.86%	26.21%	18.15%

Summary

MiMedx Group beats Pulmonx on 14 of the 18 factors compared between the two stocks.